注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Viracta Therapeutics Inc是一家臨床階段的精準腫瘤學公司。該公司專注於開發治療病毒相關惡性腫瘤的新藥。該公司正在對其作為治療復發/難治性Epstein-Barr病毒陽性(EBV+)淋巴瘤療法的組合候選產品進行臨床試驗。其主要候選產品是其研究藥物nanatinostat和抗病毒藥物valganciclovir(統稱為 Nana-val)的全口服聯合療法。Nana-val正在多項正在進行的臨床試驗中進行評估,包括用於治療多種複發/難治性EBV+淋巴瘤(NAVAL-1)亞型的II期一攬子試驗,以及用於治療EBV+復發和其他EBV+實體瘤的Ib/II期試驗。該公司的候選產品還包括臨床階段非共價ITK/BTK抑製劑vecabrutinib和臨床前階段PDK-1抑製劑VRx-510。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Ivor Royston | 78 | 2007 | Director |
Thomas Eric Darcy | 73 | 2021 | Independent Director |
Stephen Rubino | 66 | 2021 | Independent Director |
Barry J. Simon | 59 | 2021 | Independent Director |
Mark Andrew Rothera | 61 | 2022 | CEO, President & Director |
Roger James Pomerantz | 67 | 2020 | Independent Chairman of the Board |
Robert Baiocchi | - | 2018 | Member of Scientific Advisory Board |
Ronald Levy | - | 2018 | Member of Scientific Advisory Board |
Jane F. Barlow | 63 | 2021 | Independent Director |
Daniel Douglas Von Hoff | 76 | - | Member of Scientific Advisory Board |
Lawrence S. Young | - | 2018 | Member of Scientific Advisory Board |
Pierluigi Porcu | - | 2018 | Member of Scientific Advisory Board |
Flavia Borellini | 65 | 2021 | Independent Director |
Samuel Lafayette Murphy | 46 | 2019 | Independent Director |
Carl H. June | 70 | 2018 | Member of Scientific Advisory Board |
Gavin Giovannoni | - | 2024 | Member of Scientific Advisory Board |
Shannon Kenney | - | - | Member of Scientific Advisory Board |
Jane Chung | 52 | 2022 | Independent Director |
Douglas V. Faller | - | - | Scientific Founder & Chairman of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核